These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 25584895)

  • 21. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy.
    Camp ER; Wang C; Little EC; Watson PM; Pirollo KF; Rait A; Cole DJ; Chang EH; Watson DK
    Cancer Gene Ther; 2013 Apr; 20(4):222-8. PubMed ID: 23470564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The utility of hyperthermic intra-abdominal chemotherapy with gemcitabine for the inhibition of tumor progression in an experimental model of pancreatic peritoneal carcinomatosis, in relation to their behavior with pancreatic cancer stem cells CD133+ CXCR4.
    García-Santos EP; Padilla-Valverde D; Villarejo-Campos P; Murillo-Lázaro C; Fernández-Grande E; Palomino-Muñoz T; Rodríguez-Martínez M; Amo-Salas M; Nuñez-Guerrero P; Sánchez-García S; Puerto-Puerto A; Martín-Fernández J
    Pancreatology; 2016; 16(4):632-9. PubMed ID: 27289344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Gemcitabine chemotherapy for patients with advanced or relapsed pancreatic cancer].
    Ohkawa S
    Nihon Rinsho; 2006 Jan; 64 Suppl 1():198-202. PubMed ID: 16457249
    [No Abstract]   [Full Text] [Related]  

  • 24. Enhanced antitumor effect of the combination of tumstatin gene therapy and gemcitabine in murine models.
    Yao B; He QM; Tian L; Xiao F; Jiang Y; Zhang R; Li G; Zhang L; Hou JM; Wang L; Cheng XC; Wen YJ; Kan B; Li J; Zhao X; Hu B; Zhou Q; Zhang L; Wei YQ
    Hum Gene Ther; 2005 Sep; 16(9):1075-86. PubMed ID: 16149906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice.
    Baker CH; Trevino JG; Summy JM; Zhang F; Caron A; Nesbit M; Gallick GE; Fidler IJ
    Int J Oncol; 2006 Jul; 29(1):125-38. PubMed ID: 16773192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gemcitabine doublets in advanced pancreatic cancer: should we move on?
    Rocha Lima CM; Flores AM
    J Clin Oncol; 2006 Jan; 24(3):327-9. PubMed ID: 16344312
    [No Abstract]   [Full Text] [Related]  

  • 27. Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy.
    Casneuf VF; Demetter P; Boterberg T; Delrue L; Peeters M; Van Damme N
    Oncol Rep; 2009 Jul; 22(1):105-13. PubMed ID: 19513511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring protein kinase inhibitors: unveiling gemcitabine resistance in pancreatic cancer.
    Kim YJ; Hong YB; Cho CH; Seong YS; Bae I
    Pancreas; 2012 Jul; 41(5):804-5. PubMed ID: 22695089
    [No Abstract]   [Full Text] [Related]  

  • 29. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
    Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
    Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapeutic gemcitabine doublets in pancreatic carcinoma.
    Richards DA
    Semin Oncol; 2005 Aug; 32(4 Suppl 6):S9-13. PubMed ID: 16143162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic anti-tumor effect of recombinant chicken fibroblast growth factor receptor-1-mediated anti-angiogenesis and low-dose gemcitabine in a mouse colon adenocarcinoma model.
    Zheng SJ; Zheng SP; Huang FY; Jiao CL; Wu RL
    World J Gastroenterol; 2007 May; 13(17):2484-9. PubMed ID: 17552033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
    Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
    Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.
    Hong SK; Yang SY; Yin SH; Yang KX
    Pancreas; 2014 Jan; 43(1):15-21. PubMed ID: 24326363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy.
    Hasnis E; Alishekevitz D; Gingis-Veltski S; Bril R; Fremder E; Voloshin T; Raviv Z; Karban A; Shaked Y
    Neoplasia; 2014 Jun; 16(6):501-10. PubMed ID: 24957319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ultrasound and microbubble enhanced treatment of inoperable pancreatic cancer.
    Park K
    J Control Release; 2016 Dec; 243():381. PubMed ID: 28024837
    [No Abstract]   [Full Text] [Related]  

  • 36. A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging.
    Bornmann C; Graeser R; Esser N; Ziroli V; Jantscheff P; Keck T; Unger C; Hopt UT; Adam U; Schaechtele C; Massing U; von Dobschuetz E
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):395-405. PubMed ID: 17554540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
    Singh A; Xu J; Mattheolabakis G; Amiji M
    Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Enhancing effects of celecoxib on the growth inhibition of pancreatic carcinoma by gemcitabine treatment].
    Xu G; Wu K; Wang XP; Zhao S
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):986-91. PubMed ID: 16060994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different combination schedules of gemcitabine with endostar affect antitumor efficacy.
    Peng XC; Qiu M; Wei M; Tan BX; Ge J; Zhao Y; Chen Y; Cheng K; Zhou Y; Wu Y; Gong FM; Li Q; Xu F; Bi F; Liu JY
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):239-46. PubMed ID: 21706279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antitumor effects of interferon-gamma-inducible protein 10 combined with gemcitabine].
    Mei K; Tian L; Wei YQ; Li J; Wen YJ; Kan B; Deng HX
    Ai Zheng; 2005 Apr; 24(4):397-402. PubMed ID: 15820059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.